Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Masimo Corporation    MASI

MASIMO CORPORATION

(MASI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/27/2020 11/30/2020 12/01/2020 12/02/2020 12/03/2020 Date
254.41(c) 254.49(c) 253.07(c) 254.53(c) 264.49 Last
170 358 1 305 013 329 027 190 629 258 819 Volume
+3.67% +0.03% -0.56% +0.58% +3.91% Change
More quotes
Financials (USD)
Sales 2020 1 129 M - -
Net income 2020 220 M - -
Net cash position 2020 786 M - -
P/E ratio 2020 67,3x
Yield 2020 -
Sales 2021 1 174 M - -
Net income 2021 232 M - -
Net cash position 2021 1 097 M - -
P/E ratio 2021 65,0x
Yield 2021 -
Capitalization 14 013 M 14 013 M -
EV / Sales 2020 11,7x
EV / Sales 2021 11,0x
Nbr of Employees 1 600
Free-Float 72,1%
More Financials
Company
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company's business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical... 
More about the company
Notations Surperformance© of Masimo Corporation
Trading Rating : Investor Rating :
More Ratings
All news about MASIMO CORPORATION
11/30MASIMO : to Present in Piper Sandler Virtual Healthcare Conference
BU
11/30MASIMO : Study Comparing Two Noninvasive Indicators of Fluid Responsiveness on M..
BU
11/16MASIMO : to Present in Stifel Virtual Healthcare Conference
BU
11/16MASIMO : Study Investigates Effects of Patient Blood Management Program with Mas..
BU
11/09MASIMO : Founder and CEO and Co-Inventor of Measure-Through-Motion Pulse Oximetr..
BU
11/02MASIMO CORP : Other Events (form 8-K)
AQ
11/02MASIMO : Announces Limited Market Release of Radius VSM™
BU
10/29MASIMO CORP : Change in Directors or Principal Officers (form 8-K)
AQ
10/27MASIMO : Management's Discussion and Analysis of Financial Condition and Results..
AQ
10/27MASIMO : 3Q Earnings Snapshot
AQ
10/27MASIMO CORP : Results of Operations and Financial Condition (form 8-K)
AQ
10/27MASIMO : Reports Third Quarter 2020 Financial Results
BU
10/20MASIMO : to Report Third Quarter 2020 Financial Results after Market Close on Tu..
BU
10/19MASIMO : Dr. Augusto Sola, Masimo VP of Medical Affairs for Neonatology, Honored..
BU
10/12MASIMO : Researchers Use Masimo ORi™, Oxygen Reserve Index, to Predict the..
BU
More news
News in other languages on MASIMO CORPORATION
12/01MASIMO : Une étude comparant deux indicateurs non invasifs de la réactivité aux ..
12/01MASIMO : Studie zum Vergleich zweier nichtinvasiver Indikatoren der Flüssigkeits..
11/17MASIMO : Studie untersucht Auswirkungen des Patientenblutmanagementprogramms mit..
11/17MASIMO : Une étude examine les effets d'un programme de gestion du sang des pati..
11/03MASIMO : kündigt die begrenzte Markteinführung von Radius VSM™ an
More news
Stock Trading Strategies
MASIMO CORPORATION - 01/15
The trend should continue
BUY
More Stock Trading Analysis
Chart MASIMO CORPORATION
Duration : Period :
Masimo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MASIMO CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 267,29 $
Last Close Price 254,53 $
Spread / Highest target 13,9%
Spread / Average Target 5,01%
Spread / Lowest Target -23,4%
EPS Revisions
Managers
NameTitle
Joe E. Kiani Chairman & Chief Executive Officer
Bilal Muhsin Chief Operating Officer
Micah Young Chief Financial Officer & Executive Vice President
Yongsam Lee Chief Information Officer & Executive VP
Anand Sampath Executive VP-Operations & Clinical Research
Sector and Competitors
1st jan.Capitalization (M$)
MASIMO CORPORATION61.03%14 013
NOVOCURE LIMITED54.53%13 256
ASAHI INTECC CO., LTD.14.06%9 100
PENUMBRA, INC.24.94%7 453
GETINGE AB4.25%5 809
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.39.67%4 335